{"transactions":[{"id":692110,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":165519,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting\nPerson is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":165519},"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692109,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":2066857,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power\nwith regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other\npurpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2066857},"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692108,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1484401,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting\nPerson is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1484401},"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692107,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":3464072,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting\nPerson is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3464072},"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692106,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1027635,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting\nPerson is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1027635},"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692105,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":3547842,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting\nPerson is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3547842},"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692104,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Convertible Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":938979,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting\nPerson is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938979},"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692103,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":2066857,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power\nwith regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other\npurpose."}],"balance_after":2094813,"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692102,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":165519,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting\nPerson is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":5160847,"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692101,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1484401,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting\nPerson is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":4995328,"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692100,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":3464072,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting\nPerson is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":3510927,"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692099,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1027635,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting\nPerson is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":5944009,"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692098,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":3547842,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting\nPerson is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":4916374,"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":692097,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T00:00:06.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":938979,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock\nupon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting\nPerson is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":1368532,"source":{"system":"sec-edgar","filing":"0001184592-26-000005","document":"form4-08102026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000118459226000005/form4-08102026_080801.xml","form_type":"4"}},{"id":737603,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:23:34.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074055","document":"tm2617570-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465926074055/tm2617570-6_4seq1.xml","form_type":"4"}},{"id":758581,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:30:07.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":20582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":20582,"derivative":{"exercise_price":8.59,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":20582},"source":{"system":"sec-edgar","filing":"0001193125-26-248429","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000119312526248429/ownership.xml","form_type":"4"}},{"id":758580,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:30:07.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":21727,"source":{"system":"sec-edgar","filing":"0001193125-26-248429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000119312526248429/ownership.xml","form_type":"4"}},{"id":763455,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:22:04.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001184592-26-000002","document":"form4-05262026_080559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000118459226000002/form4-05262026_080559.xml","form_type":"4"}},{"id":960795,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T16:43:43.000Z","date":"2025-12-18","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":7.5,"value":999997.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":869317,"source":{"system":"sec-edgar","filing":"0001104659-25-123597","document":"tm2534053-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465925123597/tm2534053-2_4seq1.xml","form_type":"4"}},{"id":1116145,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:42:20.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":32250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32250,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":32250},"source":{"system":"sec-edgar","filing":"0001104659-25-058225","document":"tm2517621-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465925058225/tm2517621-6_4seq1.xml","form_type":"4"}},{"id":1116144,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:42:20.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":28522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":28522,"derivative":{"exercise_price":5.56,"expiration_date":"2035-06-05","underlying":"Series A Common Stock","underlying_shares":28522},"source":{"system":"sec-edgar","filing":"0001104659-25-058225","document":"tm2517621-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465925058225/tm2517621-6_4seq1.xml","form_type":"4"}},{"id":1127402,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:35:50.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080457","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017025080457/ownership.xml","form_type":"4"}},{"id":1127401,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:35:50.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080457","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017025080457/ownership.xml","form_type":"4"}},{"id":1135000,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:09:28.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92158,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-25-000062","document":"wk-form4_1748030957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000196291825000062/wk-form4_1748030957.xml","form_type":"4"}},{"id":1134999,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:09:28.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23243,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001962918-25-000062","document":"wk-form4_1748030957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000196291825000062/wk-form4_1748030957.xml","form_type":"4"}},{"id":1134998,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:09:28.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9790729,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with Alumis, Inc., a Delaware corporation (\"Parent\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Parent, par value $0.0001 per share (\"Parent Common Stock\"), and cash in lieu of any fractional shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person is the Managing Director of Westlake GP II and has sole voting and dispositive power over the shares held by Westlake Fund II, and disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001962918-25-000062","document":"wk-form4_1748030957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000196291825000062/wk-form4_1748030957.xml","form_type":"4"}},{"id":1134997,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:09:28.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with Alumis, Inc., a Delaware corporation (\"Parent\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Parent, par value $0.0001 per share (\"Parent Common Stock\"), and cash in lieu of any fractional shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001962918-25-000062","document":"wk-form4_1748030957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000196291825000062/wk-form4_1748030957.xml","form_type":"4"}},{"id":1145047,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:10:20.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013417","document":"form4-05162025_080516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588925013417/form4-05162025_080516.xml","form_type":"4"}},{"id":1379316,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-10-30T20:06:24.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":202,"price":49.5406,"value":10007.2012,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $49.70, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":131553,"source":{"system":"sec-edgar","filing":"0001415889-24-025746","document":"form4-10302024_081020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588924025746/form4-10302024_081020.xml","form_type":"4"}},{"id":1379315,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-10-30T20:06:24.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":14798,"price":48.0123,"value":710486.0154,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.30, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":131755,"source":{"system":"sec-edgar","filing":"0001415889-24-025746","document":"form4-10302024_081020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588924025746/form4-10302024_081020.xml","form_type":"4"}},{"id":1401492,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-20T20:45:32.000Z","date":"2024-09-19","kind":"sale","planned":true,"acquired":false,"shares":13823,"price":42.3058,"value":584793.0734,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.79, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":146553,"source":{"system":"sec-edgar","filing":"0001415889-24-023779","document":"form4-09202024_080929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588924023779/form4-09202024_080929.xml","form_type":"4"}},{"id":1401491,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-20T20:45:32.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":1476,"price":42,"value":61992.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"On April 10, 2024 and June 5, 2024, an aggregate of 5,488 Shares were received as part of a pro-rata in-kind distribution without consideration from XVI Associates, the managing member of KPCB XVI and XVI Founders.  The Reporting Person is one of the five managing members of XVI Associates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares are held by the Samuel B. Seidenberg Irrevocable Trust, established on July 1, 2013, for which the Reporting Person and her spouse serve as trustees."}],"balance_after":4012,"source":{"system":"sec-edgar","filing":"0001415889-24-023779","document":"form4-09202024_080929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588924023779/form4-09202024_080929.xml","form_type":"4"}},{"id":1401490,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-20T20:45:32.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":1177,"price":42.0119,"value":49448.0063,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.07, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In prior reports, the Reporting Person reported indirect beneficial ownership of 1,949,295 shares of Class A Common Stock (the \"Shares\") held by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and KPCB XVI Founders Fund, LLC (\"XVI Founders\"), whose managing member is KPCB XVI Associates, LLC (\"XVI Associates\").  On April 10, 2024, KPCB XVI and XVI Founders made a pro-rata in-kind distribution of 750,000 Shares without consideration to its members, including XVI Associates, and likewise on June 5, 2024, they made an additional pro-rata in-kind distribution of 1,199,295 Shares to its members, including XVI Associates."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On April 10, 2024, April 12, 2024, June 5, 2024 and June 13, 2024, the Reporting Person received an aggregate of 161,553 Shares as part of a pro-rata in-kind distribution without consideration from KPCB XVI, XVI Founders and their managing member, XVI Associates.  The Reporting Person is one of the five managing members of XVI Associates."}],"balance_after":160376,"source":{"system":"sec-edgar","filing":"0001415889-24-023779","document":"form4-09202024_080929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588924023779/form4-09202024_080929.xml","form_type":"4"}},{"id":1483198,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-06-12T01:07:02.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":92158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":92158,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-24-000097","document":"wk-form4_1718154414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000196291824000097/wk-form4_1718154414.xml","form_type":"4"}},{"id":1486407,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:07:35.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":51459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":51459,"derivative":{"exercise_price":4.64,"expiration_date":"2034-06-04","underlying":"Series A Common Stock","underlying_shares":51459},"source":{"system":"sec-edgar","filing":"0001104659-24-069637","document":"tm2416701-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465924069637/tm2416701-4_4seq1.xml","form_type":"4"}},{"id":1500150,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T01:50:30.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":26926,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date."}],"balance_after":26926,"derivative":{"exercise_price":27.15,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":26926},"source":{"system":"sec-edgar","filing":"0001551306-24-000122","document":"wk-form4_1716947422.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000155130624000122/wk-form4_1716947422.xml","form_type":"4"}},{"id":1500149,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-29T01:50:30.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":7206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Issuer common stock underlying restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date."}],"balance_after":43416,"source":{"system":"sec-edgar","filing":"0001551306-24-000122","document":"wk-form4_1716947422.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000155130624000122/wk-form4_1716947422.xml","form_type":"4"}},{"id":1510935,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-17T20:17:15.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":42.69,"expiration_date":"2034-05-14","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-24-013498","document":"form4-05172024_080552.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588924013498/form4-05172024_080552.xml","form_type":"4"}},{"id":1642790,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":3349538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":735984},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642789,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4006624,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":880364},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642788,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":8830901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1940388},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642787,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4401771,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":967188},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642786,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":735984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":735984,"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642785,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":3787940,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":3787940,"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1825632,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":23216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option are fully vested and exercisable as of the date hereof."}],"balance_after":23216,"derivative":{"exercise_price":6.36,"expiration_date":"2029-04-28","underlying":"Series A Common Stock","underlying_shares":23216},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825631,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2029-04-28","underlying":"Common Stock","underlying_shares":23216},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825630,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series F Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":20430107,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":257052},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825629,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series E Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":103127234,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":1297549},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825628,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series E Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":6737254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Shares held directly by the Reporting Person. Such shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\"."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":84768},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825627,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":6103580,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":76796},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825626,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":8596589,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":108163},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825625,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":8596590,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":108163},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825624,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":493370,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":6208},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825623,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":539006,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":6781},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825622,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"purchase","planned":false,"acquired":true,"shares":46875,"price":16,"value":750000.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by the Seidenberg/Vogel Revocable Trust UA 3/6/03, of which the Reporting Person serves as a trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":46875,"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825621,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":true,"shares":84768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Shares held directly by the Reporting Person. Such shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\"."}],"balance_after":84768,"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825620,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":true,"shares":1860712,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":1899475,"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825619,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":38763,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":38763,"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825618,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38763,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1843363,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-27T20:57:52.000Z","date":"2023-06-23","kind":"other","planned":false,"acquired":true,"shares":10284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership as a result of the receipt by the Reporting Person of shares in the Fund Distribution."}],"balance_after":36210,"source":{"system":"sec-edgar","filing":"0001628280-23-023606","document":"wf-form4_168789945447142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023023606/wf-form4_168789945447142.xml","form_type":"4"}},{"id":1843362,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-27T20:57:52.000Z","date":"2023-06-23","kind":"other","planned":false,"acquired":false,"shares":17162,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by KPCB XIII Associates, LLC (\"XIII Associates\") without consideration to its members (\"Fund Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by XIII Associates."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-23-023606","document":"wf-form4_168789945447142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023023606/wf-form4_168789945447142.xml","form_type":"4"}},{"id":1857043,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T01:20:02.000Z","date":"2023-06-09","kind":"other","planned":false,"acquired":true,"shares":6656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a change in the form of ownership as a result of the receipt by XIII Associates of shares in the Fund Distribution."}],"balance_after":25926,"source":{"system":"sec-edgar","filing":"0001628280-23-022017","document":"wf-form4_168670559137775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023022017/wf-form4_168670559137775.xml","form_type":"4"}},{"id":1857042,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T01:20:02.000Z","date":"2023-06-09","kind":"other","planned":false,"acquired":false,"shares":247446,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata in-kind distribution of common stock of the Issuer by XIII Associates without consideration to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of 17,162 shares of common stock of the Issuer held by XIII Associates."}],"balance_after":17162,"source":{"system":"sec-edgar","filing":"0001628280-23-022017","document":"wf-form4_168670559137775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023022017/wf-form4_168670559137775.xml","form_type":"4"}},{"id":1857041,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T01:20:02.000Z","date":"2023-06-09","kind":"other","planned":false,"acquired":true,"shares":264608,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership as a result of the receipt by XIII Associates of shares in the Fund Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Consists of 264,608 shares of common stock of the Issuer held by XIII Associates."}],"balance_after":264608,"source":{"system":"sec-edgar","filing":"0001628280-23-022017","document":"wf-form4_168670559137775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023022017/wf-form4_168670559137775.xml","form_type":"4"}},{"id":1857040,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T01:20:02.000Z","date":"2023-06-09","kind":"other","planned":false,"acquired":false,"shares":1398900,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of common stock of the Issuer by Kleiner Perkins Caufield & Byers XIII, LLC (\"KPCB XIII\") without consideration to its members (the \"Fund Distribution\"). Excludes 101,100 shares of common stock for which a change in the form of beneficial ownership for individuals and entities associated with Kleiner Perkins Caufield & Byers occurred."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by KPCB XIII. All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee.\" The managing member of KPCB XIII is KPCB XIII Associates, LLC (\"XIII Associates\"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 366,748 shares of common stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of \"KPCB Holdings, Inc. as nominee,\" for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares."}],"balance_after":5074615,"source":{"system":"sec-edgar","filing":"0001628280-23-022017","document":"wf-form4_168670559137775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023022017/wf-form4_168670559137775.xml","form_type":"4"}},{"id":1869337,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2023-06-03T00:06:15.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":79500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":79500,"derivative":{"exercise_price":1.53,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":79500},"source":{"system":"sec-edgar","filing":"0001140361-23-028161","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000114036123028161/form4.xml","form_type":"4"}},{"id":1869336,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-03T00:06:15.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":115689,"source":{"system":"sec-edgar","filing":"0001140361-23-028161","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000114036123028161/form4.xml","form_type":"4"}},{"id":1871746,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T20:20:37.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":3261,"price":19.93,"value":64991.73,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was issued to the Reporting Person in lieu of annual retainers for board and committee service. The shares underlying the option reflect payment of the Reporting Person's annual retainer of $64,984."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the Option shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":3261,"derivative":{"exercise_price":38.24,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":3261},"source":{"system":"sec-edgar","filing":"0001628280-23-020505","document":"wf-form4_168565081002134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023020505/wf-form4_168565081002134.xml","form_type":"4"}},{"id":1871745,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T20:20:37.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":19709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the Option shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":19709,"derivative":{"exercise_price":38.24,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":19709},"source":{"system":"sec-edgar","filing":"0001628280-23-020505","document":"wf-form4_168565081002134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023020505/wf-form4_168565081002134.xml","form_type":"4"}},{"id":1871744,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T20:20:37.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":5116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Issuer common stock underlying restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":19270,"source":{"system":"sec-edgar","filing":"0001628280-23-020505","document":"wf-form4_168565081002134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828023020505/wf-form4_168565081002134.xml","form_type":"4"}},{"id":1894846,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-12T20:18:32.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":20000,"derivative":{"exercise_price":7.7,"expiration_date":"2033-05-09","underlying":"Class A Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-029038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123029038/doc4.xml","form_type":"4"}},{"id":1896544,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F6","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1896543,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F6","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1896542,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":false,"shares":2038148,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F6","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2038148},"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1896541,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":false,"shares":2445786,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F6","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2445786},"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1896540,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":false,"shares":4056795,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F6","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4056795},"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1896539,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":18,"value":1080000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents shares of Common Stock purchased through a directed share program in the IPO."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1896538,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":1250000,"price":18,"value":22500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":9790729,"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1896537,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T01:13:53.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":true,"shares":8540729,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":8540729,"source":{"system":"sec-edgar","filing":"0001209191-23-028884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123028884/doc4.xml","form_type":"4"}},{"id":1904198,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-05T00:21:43.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-027537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123027537/doc4.xml","form_type":"4"}},{"id":1932074,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-03T20:05:43.000Z","date":"2023-03-30","kind":"purchase","planned":false,"acquired":true,"shares":2300,"price":7.2395,"value":16650.85,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows:  2,224 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 76 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.23 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,884,776 shares of Class A Common Stock held by KPCB XVI and 64,519 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1949295,"source":{"system":"sec-edgar","filing":"0001209191-23-022150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123022150/doc4.xml","form_type":"4"}},{"id":1934893,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-30T20:07:38.000Z","date":"2023-03-28","kind":"purchase","planned":false,"acquired":true,"shares":23908,"price":7.2441,"value":173191.9428,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows:  23,117 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 791 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.18 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,882,552 shares of Class A Common Stock held by KPCB XVI and 64,443 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1946995,"source":{"system":"sec-edgar","filing":"0001209191-23-021609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123021609/doc4.xml","form_type":"4"}},{"id":1936687,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-28T20:05:51.000Z","date":"2023-03-27","kind":"purchase","planned":false,"acquired":true,"shares":1633,"price":7.2445,"value":11830.2685,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares were purchased as follows: 1,579 shares by KPCB XVI and 54 shares by XVI Founders. All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.23 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of 1,859,435 shares of Class A Common Stock held by KPCB XVI and 63,652 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1923087,"source":{"system":"sec-edgar","filing":"0001209191-23-021386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123021386/doc4.xml","form_type":"4"}},{"id":1936686,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-28T20:05:51.000Z","date":"2023-03-24","kind":"purchase","planned":false,"acquired":true,"shares":1833,"price":7.2405,"value":13271.8365,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows:  1,772 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 61 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.20 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,857,856 shares of Class A Common Stock held by KPCB XVI and 63,598 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1921454,"source":{"system":"sec-edgar","filing":"0001209191-23-021386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123021386/doc4.xml","form_type":"4"}},{"id":1942800,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-21T20:40:40.000Z","date":"2023-03-20","kind":"purchase","planned":false,"acquired":true,"shares":15252,"price":7.2143,"value":110032.5036,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares were purchased as follows: 14,747 shares by KPCB XVI and 505 shares by XVI Founders. All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.14 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of 1,856,084 shares of Class A Common Stock held by KPCB XVI and 63,537 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1919621,"source":{"system":"sec-edgar","filing":"0001209191-23-020280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123020280/doc4.xml","form_type":"4"}},{"id":1942799,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-21T20:40:40.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":74045,"price":7.1157,"value":526882.0065,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 71,594 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 2,451 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $6.96 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,841,337 shares of Class A Common Stock held by KPCB XVI and 63,032 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1904369,"source":{"system":"sec-edgar","filing":"0001209191-23-020280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123020280/doc4.xml","form_type":"4"}},{"id":1946435,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-17T20:10:04.000Z","date":"2023-03-16","kind":"purchase","acquired":true,"shares":60097,"price":7.093,"value":426268.021,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares were purchased as follows: 58,108 shares by KPCB XVI and 1,989 shares by XVI Founders. All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $6.84 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of 1,769,743 shares of Class A Common Stock held by KPCB XVI and 60,581 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1830324,"source":{"system":"sec-edgar","filing":"0001209191-23-019611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123019611/doc4.xml","form_type":"4"}},{"id":1946434,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-17T20:10:04.000Z","date":"2023-03-15","kind":"purchase","acquired":true,"shares":32844,"price":7.1249,"value":234010.2156,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 31,757 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 1,087 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.08 to $7.15. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,711,635 shares of Class A Common Stock held by KPCB XVI and 58,592 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1770227,"source":{"system":"sec-edgar","filing":"0001209191-23-019611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123019611/doc4.xml","form_type":"4"}},{"id":1953864,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-14T20:05:23.000Z","date":"2023-03-10","kind":"purchase","acquired":true,"shares":48003,"price":7.1555,"value":343485.4665,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 46,414 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 1,589 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.06 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,679,878 shares of Class A Common Stock held by KPCB XVI and 57,505 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1737383,"source":{"system":"sec-edgar","filing":"0001209191-23-018409","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123018409/doc4.xml","form_type":"4"}},{"id":1965413,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-07T21:07:06.000Z","date":"2023-03-03","kind":"purchase","acquired":true,"shares":1000,"price":7.245,"value":7245.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 967 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 33 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.23 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,633,464 shares of Class A Common Stock held by KPCB XVI and 55,916 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1689380,"source":{"system":"sec-edgar","filing":"0001209191-23-016702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123016702/doc4.xml","form_type":"4"}},{"id":1972486,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-03T21:07:27.000Z","date":"2023-03-02","kind":"purchase","acquired":true,"shares":23378,"price":7.2428,"value":169322.1784,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares were purchased as follows: 22,604 shares by KPCB XVI and 774 shares by XVI Founders. All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.22 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Consists of 1,632,497 shares of Class A Common Stock held by KPCB XVI and 55,883 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1688380,"source":{"system":"sec-edgar","filing":"0001209191-23-015418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123015418/doc4.xml","form_type":"4"}},{"id":1972485,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-03T21:07:27.000Z","date":"2023-03-01","kind":"purchase","acquired":true,"shares":100,"price":7.25,"value":725.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 97 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 3 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 1,609,893 shares of Class A Common Stock held by KPCB XVI and 55,109 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1665002,"source":{"system":"sec-edgar","filing":"0001209191-23-015418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123015418/doc4.xml","form_type":"4"}},{"id":1989940,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-27T21:07:12.000Z","date":"2023-02-23","kind":"purchase","acquired":true,"shares":200,"price":7.235,"value":1447.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 193 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 7 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.22 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,609,796 shares of Class A Common Stock held by KPCB XVI and 55,106 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1664902,"source":{"system":"sec-edgar","filing":"0001209191-23-013159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123013159/doc4.xml","form_type":"4"}},{"id":2013323,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-15T23:32:44.000Z","date":"2023-02-13","kind":"purchase","acquired":true,"shares":10072,"price":7.1972,"value":72490.1984,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 9,739 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 333 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.1096 to $7.2500. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,609,603 shares of Class A Common Stock held by KPCB XVI and 55,099 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1664702,"source":{"system":"sec-edgar","filing":"0001209191-23-009873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123009873/doc4.xml","form_type":"4"}},{"id":2019597,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-13T21:04:54.000Z","date":"2023-02-09","kind":"purchase","acquired":true,"shares":400,"price":7.25,"value":2900.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 387 shares by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 13 shares by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 1,599,864 shares of Class A Common Stock held by KPCB XVI and 54,766 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1654630,"source":{"system":"sec-edgar","filing":"0001209191-23-008685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123008685/doc4.xml","form_type":"4"}},{"id":2024530,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-09T21:36:02.000Z","date":"2023-02-08","kind":"purchase","acquired":true,"shares":45357,"price":7.22,"value":327477.54,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"The shares were purchased as follows: 43,856 by KPCB XVI and 1,501 by XVI Founders."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.06 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Consists of 1,599,477 shares of Class A Common Stock held by KPCB XVI and 54,753 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1654230,"source":{"system":"sec-edgar","filing":"0001209191-23-008025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123008025/doc4.xml","form_type":"4"}},{"id":2024529,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-09T21:36:02.000Z","date":"2023-02-07","kind":"purchase","acquired":true,"shares":87956,"price":7.08,"value":622728.48,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares were purchased as follows: 85,045 by KPCB XVI and 2,911 by XVI Founders."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $6.97 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Consists of 1,555,621 shares of Class A Common Stock held by KPCB XVI and 53,252 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1608873,"source":{"system":"sec-edgar","filing":"0001209191-23-008025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123008025/doc4.xml","form_type":"4"}},{"id":2024528,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-09T21:36:02.000Z","date":"2023-02-06","kind":"purchase","acquired":true,"shares":131602,"price":7.03,"value":925162.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares were purchased as follows: 127,246 by KPCB XVI and 4,356 by XVI Founders."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $6.86 to $7.24. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of 1,470,576 shares of Class A Common Stock held by KPCB XVI and 50,341 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1520917,"source":{"system":"sec-edgar","filing":"0001209191-23-008025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123008025/doc4.xml","form_type":"4"}},{"id":2024527,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-09T21:36:02.000Z","date":"2023-02-03","kind":"purchase","acquired":true,"shares":46163,"price":7.24,"value":334220.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased as follows: 44,635 by Kleiner Perkins Caufield & Byers XVI, LLC (\"KPCB XVI\") and 1,528 by KPCB XVI Founders Fund, LLC (\"XVI Founders\"). All shares are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC (\"XVI Associates\"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders.  Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average purchase price. The shares were purchased at prices ranging from $7.21 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,343,330 shares of Class A Common Stock held by KPCB XVI and 45,985 shares of Class A Common Stock held by XVI Founders."}],"balance_after":1389315,"source":{"system":"sec-edgar","filing":"0001209191-23-008025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000120919123008025/doc4.xml","form_type":"4"}},{"id":2131555,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-26T21:40:10.000Z","date":"2022-10-24","kind":"grant","acquired":true,"shares":1898,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was issued to the Reporting Person in lieu of annual retainers for board and committee service. The shares underlying the option reflect the payment in full of the Reporting Person's annual retainers of $37,749.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the Option shall vest on May 23, 2023, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":1898,"derivative":{"exercise_price":38.22,"expiration_date":"2032-10-23","underlying":"Common Stock","underlying_shares":1898},"source":{"system":"sec-edgar","filing":"0001628280-22-027105","document":"wf-form4_166682038835521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000162828022027105/wf-form4_166682038835521.xml","form_type":"4"}}],"next_cursor":"2022-10-26T21:40:10.000000Z,2131555"}